Abstract: A method for administering a cone contrast color vision test to a patient using a computer, including displaying a first character in a color at a first contrast level on a display connected to the computer, receiving a first input signal from the patient via an input device that indicates whether the patient recognizes the first character, displaying a second character in the color at a second contrast level which is not equivalent to the first contrast level, receiving a second input signal from the patient that indicates whether the patient recognizes the second character, assigning a score related to a cone sensitivity of the patient to the color at the first and second contrast levels, storing the score in a storage device, and comparing the score to at least one previous score from the patient to calculate a progression of a cone sensitivity loss.

Abstract: A method and apparatus for administering eye tests to identify cone sensitivity loss associated with hereditary and acquired color vision loss which may be used for early detection, progress, treatment, and monitoring of eye conditions, traumatic brain injury, optic neuritis, systemic and neurological diseases including Glaucoma, Retinopathy, Age-Related Macular Degeneration, Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease and retinal toxicity. Particularly, the method and apparatus disclosed uses a Cone Contrast Test (CCT) to test individuals for hereditary or acquired color vision loss associated with (a) early signs of potential disease/damage/toxicity in an effort to (i) provide opportunity for treatment, and (ii) prevent permanent eye damage, and (b) monitor progress and treatment of such disease/damage/toxicity.

Abstract: A method and apparatus for administering eye tests to identify cone sensitivity loss associated with hereditary and acquired color vision loss which may be used for early detection, progress, treatment, and monitoring of eye conditions, traumatic brain injury, optic neuritis, systemic and neurological diseases including Glaucoma, Retinopathy, Age-Related Macular Degeneration, Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease and retinal toxicity. Particularly, the method and apparatus disclosed uses a Cone Contrast Test (CCT) to test individuals for hereditary or acquired color vision loss associated with (a) early signs of potential disease/damage/toxicity in an effort to (i) provide opportunity for treatment, and (ii) prevent permanent eye damage, and (b) monitor progress and treatment of such disease/damage/toxicity.